Abstract
Introduction: Hyperhidrosis is a chronic dermatologic condition that significantly impacts quality of life. While research has expanded in recent years, bibliometric analyses exploring publication trends remain limited. This study examined the 100 most-cited articles from 2015 to 2025 to assess research priorities. Methods: A Scopus search was conducted on January 2, 2025, using the terms “hyperhidrosis”, “primary hyperhidrosis”, “secondary hyperhidrosis”, and “excessive sweating”. Non-English, abstract-only, and non-hyperhidrosis focused articles were excluded. Two reviewers screened and identified the 100 most-cited publications. Data were analyzed for publication year, authorship, country, study design, journal, and topic focus. The Oxford Centre for Evidence-Based Medicine Level of Evidence (LoE) framework was used to assess study quality. Results: The majority (76%) of highly cited articles were published between 2015 and 2019. Randomized controlled trials (20%), cohort studies (18%), and case-control studies (16%) were the most common study types. Using LoE assessment, 33% of studies were level 1 (high-quality evidence). Research on treatments (55%) dominated, followed by quality of life (12%) and outcome measures (11%). The USA led in publication output. Conclusion: This bibliometric analysis identifies evolving research priorities toward minimally invasive treatments and patient-centered outcomes, providing direction for future research and improvements in clinical practice.
Journal Section:
Research Article
References
1.
Oshima
Y
, Fujimoto
T
, Nomoto
M
, Fukui
J
, Ikoma
A
. Hyperhidrosis: a targeted literature review of the disease burden
. J Dermatol
. 2023
;50
(10
):1227
–36
. 2.
OCEBM levels of evidence — Centre for evidence-based medicine (CEBM)
. University of Oxford
[cited 2025 Jan 13]. Available from: https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence3.
Nawrocki
S
, Cha
J
. The etiology, diagnosis, and management of hyperhidrosis: a comprehensive review: therapeutic options
. J Am Acad Dermatol
. 2019
;81
(3
):669
–80
. 4.
Glaser
DA
, Hebert
AA
, Nast
A
, Werschler
WP
, Green
L
, Mamelok
R
, et al. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials
. J Am Acad Dermatol
. 2019
;80
(1
):128
–38.e2
. 5.
Schollhammer
M
, Brenaut
E
, Menard-Andivot
N
, Pillette-Delarue
M
, Zagnoli
A
, Chassain-Le Lay
M
, et al. Oxybutynin as a treatment for generalized hyperhidrosis: a randomized, placebo-controlled trial
. Br J Dermatol
. 2015
;173
(5
):1163
–8
. 6.
Pariser
DM
, Hebert
AA
, Drew
J
, Quiring
J
, Gopalan
R
, Glaser
DA
. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: patient-reported outcomes from the ATMOS-1 and ATMOS-2 phase III randomized controlled trials
. Am J Clin Dermatol
. 2019
;20
(1
):135
–45
. 7.
Glaser
DA
, Hebert
AA
, Nast
A
, Werschler
WP
, Green
L
, Mamelok
RD
, et al. A 44-week open-label study evaluating safety and efficacy of topical glycopyrronium tosylate in patients with primary axillary hyperhidrosis
. Am J Clin Dermatol
. 2019
;20
(4
):593
–604
. 8.
Artzi
O
, Loizides
C
, Zur
E
, Sprecher
E
. Topical oxybutynin 10% gel for the treatment of primary focal hyperhidrosis: a randomized double-blind placebo-controlled split area study
. Acta Derm Venereol
. 2017
;97
(9
):1120
–4
. 9.
Glycopyrronium tosylate in pediatric primary axillary hyperhidrosis: post hoc analysis of efficacy and safety findings by age from two phase three randomized controlled trials
. Pediatr Dermatol
. 2019
;36
(4
):89
–99
. 10.
Lueangarun
S
, Sermsilp
C
, Tempark
T
. Topical botulinum toxin type A liposomal cream for primary axillary hyperhidrosis: a double-blind, randomized, split-site, vehicle-controlled study
. Dermatol Surg
. 2018
;44
(8
):1094
–101
. 11.
Abels
C
, Soeberdt
M
, Kilic
A
, Reich
H
, Knie
U
, Jourdan
C
, et al. A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial
. Br J Dermatol
. 2021
;185
(2
):315
–22
. 12.
Kaminaka
C
, Mikita
N
, Inaba
Y
, Kunimoto
K
, Okuhira
H
, Jinnin
M
, et al. Clinical and histological evaluation of a single high energy microwave treatment for primary axillary hyperhidrosis in Asians: a prospective, randomized, controlled, split-area comparative trial
. Lasers Surg Med
. 2019
;51
(7
):592
–9
. 13.
Yokozeki
H
, Fujimoto
T
, Abe
Y
, Igarashi
M
, Ishikoh
A
, Omi
T
, et al. A phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel-group study of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis
. J Dermatol
. 2021
;48
(3
):279
–88
. 14.
Rummaneethorn
P
, Chalermchai
T
. A comparative study between intradermal botulinum toxin A and fractional microneedle radiofrequency (FMR) for the treatment of primary axillary hyperhidrosis
. Lasers Med Sci
. 2020
;35
(5
):1179
–84
. 15.
Junsuwan
N
, Manuskiatti
W
, Phothong
W
, Wanitphakdeedecha
R
. Fractional CO2 laser-assisted Botulinum toxin type A delivery for the treatment of primary palmar hyperhidrosis
. Lasers Med Sci
. 2021
;36
(1
):233
–6
. 16.
Salim
EF
, Ali
GA
. Impact of thoracoscopic T2 sympathectomy on patients with primary palmar and axillary hyperhidrosis
. Ann Thorac Surg
. 2018
;106
(4
):1032
–7
. 17.
Hebert
AA
, Glaser
DA
, Green
L
, Hull
C
, Cather
J
, Drew
J
, et al. Long-term efficacy and safety of topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: post hoc pediatric subgroup analysis from a 44-week open-label extension study
. Pediatr Dermatol
. 2020
;37
(3
):490
–7
. 18.
Pariser
DM
, Lain
EL
, Mamelok
RD
, Drew
J
, Mould
DR
. Limited systemic exposure with topical glycopyrronium tosylate in primary axillary hyperhidrosis
. Clin Pharmacokinet
. 2021
;60
(5
):665
–76
. 19.
Mostafa
TAH
, Hamed
AA
, Mohammed
BM
, El Sheikh
NA
, Shama
AAA
. C-arm guided percutaneous radiofrequency thoracic sympathectomy for treatment of primary palmar hyperhidrosis in comparison with local botulinum toxin type a injection, randomized trial
. Pain Physician
. 2019
;22
(6
):591
–9
.20.
Fujimoto
T
, Terahara
T
, Okawa
K
, Inakura
H
, Hirayama
Y
, Yokozeki
H
. A novel lotion formulation of 20% oxybutynin hydrochloride for the treatment of primary palmar hyperhidrosis: a randomized, placebo-controlled, double-blind, phase III study
. J Am Acad Dermatol
. 2023
;89
(1
):62
–9
. 21.
Cho
SB
, Park
J
, Zheng
Z
, Yoo
KH
, Kim
H
. Split-axilla comparison study of 0.5-MHz, invasive, bipolar radiofrequency treatment using insulated microneedle electrodes for primary axillary hyperhidrosis
. Skin Res Technol
. 2019
;25
(1
):30
–9
. 22.
Chen
JF
, Lin
M
, Chen
P
, Quan
D
, Li
X
, Lai
FC
, et al. Nonintubated needlescopic thoracic sympathectomy for primary palmar hyperhidrosis: a randomized controlled trial
. Surg Laparosc Endosc Percutan Tech
. 2016
;26
(4
):328
–33
. 23.
Yokozeki
H
, Fujimoto
T
, Wanatabe
S
, Ogawa
S
, Fujii
C
. Topical glycopyrronium tosylate in Japanese patients with primary axillary hyperhidrosis: a randomized, double-blind, vehicle-controlled study
. J Dermatol
. 2022
;49
(1
):86
–94
. 24.
Strutton
DR
, Kowalski
JW
, Glaser
DA
, Stang
PE
. US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey
. J Am Acad Dermatol
. 2004
;51
(2
):241
–8
. 25.
Henning
MAS
, Bouazzi
D
, Jemec
GBE
. Treatment of hyperhidrosis: an update
. Am J Clin Dermatol
. 2022
;23
(5
):635
–46
. © 2025 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.
